Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Operating Expenses for 4 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 13.54% to $3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.2 million, a 3.15% decrease, with the full-year FY2024 number at $18.3 million, up 74.34% from a year prior.
  • Operating Expenses was $3.7 million for Q3 2025 at bioAffinity Technologies, down from $3.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $5.2 million in Q4 2024 to a low of $685279.0 in Q2 2022.
  • A 4-year average of $3.0 million and a median of $3.7 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 180.12% in 2023, then fell 15.62% in 2025.
  • bioAffinity Technologies' Operating Expenses stood at $1.6 million in 2022, then skyrocketed by 180.12% to $4.6 million in 2023, then rose by 13.13% to $5.2 million in 2024, then fell by 27.46% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Operating Expenses are $3.7 million (Q3 2025), $3.8 million (Q2 2025), and $4.5 million (Q1 2025).